Camilleri M
Clinical Enteric Neuroscience Translational and Epidemiological Research Group, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Neurogastroenterol Motil. 2007 Feb;19(2):77-84. doi: 10.1111/j.1365-2982.2006.00861.x.
5-HT(3) antagonists are effective treatments for chemotherapy-induced emesis and diarrhoea and urgency and pain associated with irritable bowel syndrome. Reports of ischaemic colitis led to restricted use of the approved drug, alosetron. This article briefly reviews the controversial information from epidemiology and adverse reaction reports and addresses the experimental basis for the development of ischaemic colitis as a result of 5-HT(3) antagonist treatment. The author reviews the potential factors based involved in the ischaemic colitis and ways in which this class of compound may influence those factors based on experimental evidence, including the literature on any vascular effects of these agents. Finally, the article addresses the theoretical basis for the constipation as a predisposing factor for the development of ischaemic colitis. The evidence reviewed suggests that further studies are needed to explore the principles to prove or disprove the association.
5-羟色胺（3）拮抗剂是化疗引起的呕吐、腹泻以及与肠易激综合征相关的尿急和疼痛的有效治疗药物。缺血性结肠炎的报告导致已获批药物阿洛司琼的使用受限。本文简要回顾了来自流行病学和不良反应报告的有争议信息，并探讨了5-羟色胺（3）拮抗剂治疗导致缺血性结肠炎发生的实验依据。作者基于实验证据，包括有关这些药物血管效应的文献，回顾了缺血性结肠炎所涉及的潜在因素以及这类化合物可能影响这些因素的方式。最后，本文阐述了便秘作为缺血性结肠炎发生的诱发因素的理论依据。所回顾的证据表明，需要进一步研究以探索相关原理，来证实或反驳这种关联。
